Delivery of drugs into the central nervous system is one of the most challenging problems faced in the field of neurodegeneration treatment. Effective therapeutic strategies for neurodegenerative diseases have so far been lacking and, in many ways, inadequate. Owing to increased lifespans and population growth, central nervous system diseases are expected to increase significantly in the 21st century. This is especially true for neurodegenerative diseases, characterized by age-related gradual decline in neurological function, often accompanied by neuronal death.
Brain Trust Bio reimagines how to make existing central nervous system disease therapies more effective by optimizing the best scientific and medical innovations available. An early stage startup, Brain Trust Bio already has a proven track record and has successfully treated two patients off-label with no side effects while providing stable and prolonged neuroprotection.
Therapeutic opportunities will continue to grow as science increases the biological understanding of neurodegenerative disease. Brain Trust Bio has a clear competitive advantage and is uniquely positioned to spearhead innovation in the optimization of drug delivery with a proven way to amplify the efficacy of already approved FDA drugs.
If you would like to discuss investment opportunities with us, please contact us.